Fortress Biotech Files 8-K Report

TL;DR

FBIO filed an 8-K on Nov 4, 2024, updating corporate info.

AI Summary

On November 4, 2024, Fortress Biotech, Inc. filed an 8-K report. The filing indicates that the company is incorporated in Delaware and its principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154. The report was filed under the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing provides official updates on Fortress Biotech's corporate status and reporting requirements to the SEC.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information.

Key Players & Entities

• Fortress Biotech, Inc. (company) — Registrant
• November 4, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (address) — Principal Executive Offices
• 001-35366 (identifier) — Commission File Number

FAQ

Filing Documents

• fbio-20241104x8k.htm (8-K) — 41KB
• 0001558370-24-014186.txt ( ) — 222KB
• fbio-20241104.xsd (EX-101.SCH) — 5KB
• fbio-20241104_def.xml (EX-101.DEF) — 15KB
• fbio-20241104_lab.xml (EX-101.LAB) — 13KB
• fbio-20241104_pre.xml (EX-101.PRE) — 15KB
• fbio-20241104x8k_htm.xml (XML) — 7KB

01. Other Events

Item 8.01. Other Events . On November 4, 2024, Journey Medical Corporation (" Journey Medical "), a majority-controlled subsidiary of Fortress Biotech, Inc. (the " Company " or " Fortress "), announced that the U.S. Food and Drug Administration (the " FDA ") approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40mg) for the treatment of inflammatory lesions of rosacea in adults. Emrosi (also known as DFD-29) was developed by Journey Medical in collaboration with Dr. Reddy's Laboratories, Ltd. Journey Medical is completing the manufacturing of Emrosi for the U.S. market and anticipates initial supply will be available in the late first quarter or early second quarter of 2025. Journey Medical intends to market Emrosi in the United States with its dermatology-focused commercial organization. The approval of Emrosi is supported by positive data from Journey Medical's two Phase 3 clinical trials for the treatment of rosacea. The Phase 3 clinical trials met all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues. Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea 40mg capsules, and placebo for Investigator's Global Assessment treatment success as well as the reduction in total inflammatory lesion count in both studies. Cautionary Note Regarding Forward-Looking Statements This report may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this report, the words "we", "us" and "our" may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to the expectations regarding the use of proceeds from the offering, as well as our growth strategy and product development p

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: November 4, 2024 By: /s/ David Jin David Jin Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR